Company / Accounts Receivable
Acadia Pharmaceuticals Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$121.5M
FY2025
5-year range
$62.2M / $121.5M
FY2021-FY2025
Trend
+23.0%
vs FY2024
Sector context
#50 of 115
Health Care
What the data says
At $121M, Acadia Pharmaceuticals's accounts receivable ranks #50 of 115 in the Health Care sector. Accounts Receivable has increased for 3 consecutive years, from $62M in FY2022 to $121M in FY2025.
Based on SEC 10-K filings.
$121M in FY2025 with a 5-year CAGR of +20.3%.
Improved from $98M to $121M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +25.0%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- -
Sector benchmark
#50 of 115 in Health CareTop 43% of 115This company $121.5M Sector average $1.1B
▼
-89.1% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's accounts receivable has grown for 3 consecutive years.
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 23.0% year-over-year.
- Ranks #50 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $121.5M | +23.0% |
| FY2024 | $98.7M | +0.5% |
| FY2023 | $98.3M | +58.0% |
| FY2022 | $62.2M | -3.4% |
| FY2021 | $64.4M | +33.4% |
| FY2020 | $48.2M | +34.8% |
| FY2019 | $35.8M | +37.1% |
| FY2018 | $26.1M | +50.4% |
| FY2017 | $17.3M | +193.8% |
| FY2016 | $5.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026